Related Experiment Video
Updated: Jun 13, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
A Horiguchi1, T Asano, K Kuroda
1Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa-City, Saitama 359-8513, Japan.
Background:
Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes that mediate cell survival, proliferation, and angiogenesis and is aberrantly activated in various types of malignancies, including renal cell carcinoma (RCC). We examined whether it could be a novel therapeutic target for RCC by using the STAT3 inhibitor WP1066.
Methods:
The antitumour activities and related mechanisms of WP1066 were investigated in vitro on renal cancer cell lines and in vivo on murine xenografts.
Results:
In Caki-1 and 786-O renal cancer cells, 5 muM WP1066 prevented the phosphorylation of STAT3, and 2.5 muM WP1066 significantly (P<0.01) inhibited cell survival and proliferation. WP1066 suppressed the expression of Bcl-2, induced apoptosis, and inhibited the basal and hypoxia-induced expression of HIF1alpha and HIF2alpha, as well as vascular endothelial growth factor secretion into cell culture medium. Human umbilical vascular endothelial cells cocultured with media from WP1066-treated cells showed significantly reduced tubulogenesis (P<0.05). Systemic oral administration of WP1066 to mice for 19 days significantly inhibited the growth of Caki-1 xenograft tumours (P<0.05), and pathological analysis of xenografts of WP1066-treated mice showed decreased immunostaining of phosphorylated STAT3 and reduced length of CD34-positive vessels (P<0.05).
Conclusion:
Our results suggest that using WP1066 to inhibit the STAT3 signalling pathway could be a novel therapeutic strategy against RCC.
Insights
WP1066, a STAT3 inhibitor, demonstrated significant anti-tumor activity in renal cell carcinoma (RCC) models. It suppressed cancer cell survival, proliferation, and angiogenesis, suggesting WP1066 as a potential therapeutic strategy for RCC.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Signal transducer and activator of transcription 3 (STAT3) is crucial for cell survival and proliferation.
- Aberrant STAT3 activation is implicated in various cancers, including renal cell carcinoma (RCC).
Purpose of the Study:
- To investigate WP1066, a STAT3 inhibitor, as a potential therapeutic agent for RCC.
- To elucidate the anti-tumor mechanisms of WP1066 in RCC models.
Main Methods:
- In vitro studies on renal cancer cell lines (Caki-1, 786-O) and human umbilical vascular endothelial cells.
- In vivo studies using murine xenograft models of RCC.
- Assessment of STAT3 phosphorylation, cell survival, proliferation, apoptosis, and angiogenesis markers (Bcl-2, HIF1alpha, HIF2alpha, VEGF).
Main Results:
- WP1066 inhibited STAT3 phosphorylation, cell survival, and proliferation in RCC cell lines.
- WP1066 suppressed angiogenesis by reducing VEGF secretion and endothelial cell tubulogenesis.
- WP1066 administration significantly inhibited tumor growth in vivo and reduced STAT3 activation and angiogenesis markers in xenografts.
Conclusions:
- Inhibition of the STAT3 signaling pathway with WP1066 shows promise as a novel therapeutic strategy for renal cell carcinoma.
- WP1066 exhibits anti-tumor effects through multiple mechanisms, including direct anti-proliferative and anti-angiogenic actions.
